Today's highlights: 25 August 2010
This article was originally published in Scrip
Executive Summary
FDA hands refusal to file letter to EpiCept for lead leukaemia product
Strike date set in AstraZeneca UK pension dispute
Extended review for Acetadote supplement hits Cumberland shares
Pipeline progress at Oxford BioMedica as H1 losses reach £2.9 million
Baxter acquires alpha 1-antitrypsin therapy and technology from Kamada
Pfizer gets WHO approval for pneumocococal vaccine
Indian govt paper to reignite debate on compulsory licensing
First Phase III results for perampanel in epilepsy look positive
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.